NCT00310024View on ClinicalTrials.gov

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 29, 2008

Conditions
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

bortezomib

Given IV

DRUG

vorinostat

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

21201-1595

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00310024 - Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter